Residual lung damage after completion of treatment for multidrug-resistant tuberculosis.

Details

Ressource 1Download: s13.pdf (66.07 [Ko])
State: Public
Version: author
License: Not specified
Serval ID
serval:BIB_30DDA4D9208B
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Residual lung damage after completion of treatment for multidrug-resistant tuberculosis.
Journal
The international journal of tuberculosis and lung disease
Author(s)
de Vallière S., Barker R.D.
ISSN
1027-3719 (Print)
ISSN-L
1027-3719
Publication state
Published
Issued date
06/2004
Peer-reviewed
Oui
Volume
8
Number
6
Pages
767-771
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Limpopo Province, South Africa.
To assess the residual lung damage of patients who completed treatment for multidrug-resistant tuberculosis (MDR-TB).
Chest radiograph and lung function tests were performed at the end of treatment. The radiographs were read by two independent observers who attributed a zonal score of between 0 and 18, depending on the extent of radiographic abnormalities (opacification or cavitation), counted the number of visible cavities and measured the diameter of the largest cavity.
The mean zonal score was 6.5. Cavitation was present in more than half of the patients. Of 33 patients, 31 (94%) had abnormal lung function tests. The median FEV1 was 63% and FVC was 57% of the predicted value. Restrictive and combined restrictive-obstructive lung function patterns were the predominant abnormalities.
Residual lung damage in MDR-TB patients who completed treatment is common and extensive. This may increase the risk of relapse of tuberculosis and reduce the quality of life and life expectancy of these patients. Additional efforts are warranted to diagnose MDR-TB early to reduce the extent of residual lung damage. Close follow-up of MDR-TB patients completing treatment will have to be ensured to detect relapses.
Keywords
Adolescent, Adult, Aged, Anti-Bacterial Agents/administration & dosage, Anti-Bacterial Agents/pharmacology, Anti-Bacterial Agents/therapeutic use, Antitubercular Agents/administration & dosage, Antitubercular Agents/pharmacology, Antitubercular Agents/therapeutic use, Communicable Disease Control/methods, Drug Combinations, Female, Forced Expiratory Flow Rates/physiology, HIV Seropositivity/complications, Humans, Lung Diseases, Obstructive/diagnosis, Lung Diseases, Obstructive/diagnostic imaging, Lung Diseases, Obstructive/etiology, Male, Middle Aged, Radiography, Respiratory Function Tests, South Africa, Spirometry, Tuberculosis, Multidrug-Resistant/complications, Tuberculosis, Multidrug-Resistant/diagnostic imaging, Tuberculosis, Multidrug-Resistant/drug therapy, Tuberculosis, Multidrug-Resistant/physiopathology, Tuberculosis, Pulmonary/complications, Tuberculosis, Pulmonary/diagnostic imaging, Tuberculosis, Pulmonary/drug therapy, Tuberculosis, Pulmonary/physiopathology, Vital Capacity/physiology
Pubmed
Web of science
Create date
25/04/2022 11:21
Last modification date
26/04/2022 7:08
Usage data